Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions
These Mutations Predict Poorer Survival in CMML
Am J Hematol; ePub 2016 Dec 7; Patnaik, et al
DNMT3A mutations should be included in molecularly integrated prognostic models for people with chronic myelomonocytic leukemia (CMML), according to a study involving 261 individuals.
Investigators looked at the prognostic impact of DNMT3A mutations and found:
- DNMT3A mutations were seen in 6% of patients (median age of 64).
- ~80% of DNMT3A mutations were missense, with the Arg882 mutational hot spot accounting for 63% of all changes.
- Nearly one-third of patients with DNMT3A mutations had an abnormal karyotype.
- Patients with DNMT3A mutations survived a median of 8 months, vs 27 months in those with wildtype.
- Even when certain variables were accounted for, only DNMT3A and ASXL1 mutations remained significant.
- DNMT3A mutations were also predictive of a shortened leukemia-free survival.
Citation:
Patnaik M, Barraco D, Lasho T, et al. DNMT3A mutations are associated with inferior overall and leukemia-free survival in chronic myelomonocytic leukemia. [Published online ahead of print December 7, 2016]. Am J Hematol. doi:10.1002/ajh.24581.